Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study

Escrivá-de-Romani, S; Cejalvo, JM; Alba, E; Friedmann, J; Rodríguez-Lescure, A; Savard, MF; Pezo, RC; Gion, M; Ruiz-Borrego, M; Hamilton, E; Pluard, T; Webster, M; Beeram, M; Linden, H; Saura, C; Shpektor, D; Salim, B; Harvey, P; Hurvitz, SA – 2025 –...

Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study

García-Corbacho, J; Indacochea, A; Victoria, I; Moreno, D; Angelats, L; Navarro, AEG; Mezquita, L; Brasó-Maristany, F; Galván, P; Mellado, B; Viñolas, N; Sauri, T; Nogué, M; Adamo, B; Maurel, J; Pineda, E; Gaba, L; Reig, O; Basté, N; Sanfeliu, E; Juan, ME; Prat, A;...